ProShares Ultra NASDAQ Biotechnology
BIB
BIB
30 hedge funds and large institutions have $14.8M invested in ProShares Ultra NASDAQ Biotechnology in 2021 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 5 increasing their positions, 10 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less capital invested
Capital invested by funds: $ → $
50% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 8
50% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 10
Holders
30
Holding in Top 10
–
Calls
$7.46M
Puts
$4.16M
Top Buyers
| 1 | +$1.69M | |
| 2 | +$1.48M | |
| 3 | +$564K | |
| 4 |
Vontobel Holding
Zurich,
Switzerland
|
+$85K |
| 5 |
TCM
Traynor Capital Management
Malvern,
Pennsylvania
|
+$47.6K |
Top Sellers
| 1 | -$8.09M | |
| 2 | -$1.79M | |
| 3 | -$1.14M | |
| 4 |
TFA
Toth Financial Advisory
Leesburg,
Virginia
|
-$946K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$565K |